CSPC Pharmaceutical Group Limited
CSPCY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2 | $15 | $16 | $8 |
| % Growth | -87.5% | -10.4% | 114.6% | – |
| Cost of Goods Sold | $1 | $5 | $5 | $8 |
| Gross Profit | $1 | $10 | $12 | $19 |
| % Margin | 65.6% | 68.2% | 71.6% | 246.3% |
| R&D Expenses | $3 | $3 | $3 | $1 |
| G&A Expenses | $0 | $0 | $1 | $1 |
| SG&A Expenses | $4 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $3 | $4 | $5 | $5 |
| Other Operating Expenses | $0 | -$0 | $0 | -$3 |
| Operating Expenses | $7 | $8 | $8 | $4 |
| Operating Income | $0 | $2 | $4 | $2 |
| % Margin | 19.4% | 13.8% | 22.7% | 23.6% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | $0 | $2 | $4 | $2 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | $0 | $2 | $3 | $1 |
| % Margin | 19.2% | 10.9% | 18.5% | 18.2% |
| EPS | 0.12 | 0.48 | 1.08 | 1.44 |
| % Growth | -75% | -55.6% | -25% | – |
| EPS Diluted | 0.12 | 0.48 | 1.08 | 1.44 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | $3 | $2 | $5 | $2 |
| % Margin | 190.2% | 17.1% | 27.8% | 23.6% |